Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne L Peters

Showing results (61-70 of 125) with videos related to

Pageof 13
Sort By:
Diabetes, Obesity & Metabolism|January 30, 2018
Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 TrialsPaolo Pozzilli, Richard D Leslie, Anne L Peters, et al.
Diabetes, Obesity & Metabolism|February 14, 2023
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney diseaseDavid Z I Cherney, Ele Ferrannini, Guillermo E Umpierrez, et al.
Journal of Medical Economics|February 1, 2013
Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysisElizabeth L Eby, Ping Wang, Bradley H Curtis, et al.
Diabetes, Obesity & Metabolism|February 14, 2020
Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trialJuan P Frias, Guillermo Gonzalez-Galvez, Eva Johnsson, et al.
Diabetes Technology & Therapeutics|July 10, 2020
Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin StudyBruce W Bode, Eda Cengiz, R Paul Wadwa, et al.
The Diabetes Educator|October 9, 2018
Psychosocial and Behavioral Correlates of A1C and Quality of Life Among Young Adults With DiabetesCheryl L P Vigen, Kristine Carandang, Jeanine Blanchard, et al.
The Journal of Clinical Endocrinology and Metabolism|May 22, 2019
Mifepristone Treatment in Four Cases of Primary Bilateral Macronodular Adrenal Hyperplasia (BMAH)Pejman Cohan, Honey E East, Sandi-Jo Galati, et al.
Diabetologia|October 5, 2022
Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes AssociationJennifer L Sherr, Lutz Heinemann, G Alexander Fleming, et al.
Diabetologia|March 13, 2026
Challenges in and opportunities for individualising diabetes technology: a position statement by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working GroupDaniela Bruttomesso, John R Petrie, Mark Evans, et al.
Diabetes Care|March 12, 2026
Challenges in and Opportunities for Individualizing Diabetes Technology: A Position Statement by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working GroupDaniela Bruttomesso, John R Petrie, Mark Evans, et al.
Pageof 13

Showing results (61-70 of 125) with videos related to

Sort By:
Pageof 13
Diabetes, Obesity & Metabolism|January 30, 2018
Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 TrialsPaolo Pozzilli, Richard D Leslie, Anne L Peters, et al.
Diabetes, Obesity & Metabolism|February 14, 2023
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney diseaseDavid Z I Cherney, Ele Ferrannini, Guillermo E Umpierrez, et al.
Journal of Medical Economics|February 1, 2013
Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysisElizabeth L Eby, Ping Wang, Bradley H Curtis, et al.
Diabetes, Obesity & Metabolism|February 14, 2020
Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trialJuan P Frias, Guillermo Gonzalez-Galvez, Eva Johnsson, et al.
Diabetes Technology & Therapeutics|July 10, 2020
Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin StudyBruce W Bode, Eda Cengiz, R Paul Wadwa, et al.
The Diabetes Educator|October 9, 2018
Psychosocial and Behavioral Correlates of A1C and Quality of Life Among Young Adults With DiabetesCheryl L P Vigen, Kristine Carandang, Jeanine Blanchard, et al.
The Journal of Clinical Endocrinology and Metabolism|May 22, 2019
Mifepristone Treatment in Four Cases of Primary Bilateral Macronodular Adrenal Hyperplasia (BMAH)Pejman Cohan, Honey E East, Sandi-Jo Galati, et al.
Diabetologia|October 5, 2022
Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes AssociationJennifer L Sherr, Lutz Heinemann, G Alexander Fleming, et al.
Diabetologia|March 13, 2026
Challenges in and opportunities for individualising diabetes technology: a position statement by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working GroupDaniela Bruttomesso, John R Petrie, Mark Evans, et al.
Diabetes Care|March 12, 2026
Challenges in and Opportunities for Individualizing Diabetes Technology: A Position Statement by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working GroupDaniela Bruttomesso, John R Petrie, Mark Evans, et al.
Pageof 13